new problems for president biden in polling. his popularity is seeing is a drop in voters as they rank the biggest concerns. and president biden is leaving for a g20 summit in india and what they say he needs to pull off while there. and an american is stuck in a cave thousands of feet below ground, and the measures to rescue him. i m john berman with sara sidner and kate bolduan. this is cnn news central. oomph, problematic poll numbers for president biden, the approval numbers are sinking to 39%, and democrats are on notice as a 2024 race for the white house is heating up. among the voters concerns, age. they are worried about the physical and mental competence along with how well he understands the concerns ofuture generations of americans. another big issue, the economy. 58% say that biden s policies have made economic conditions worse. all right. with me now, cnn political director david chalian and welcome back once again. for you, what stands out? there is a l
Serving our colleagues
stanford.edu - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from stanford.edu Daily Mail and Mail on Sunday newspapers.
C L Moore | File 770
file770.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from file770.com Daily Mail and Mail on Sunday newspapers.
Novavax Nuvaxovid™ COVID-19 Vaccine Approved in South Korea for Use in Adolescents Aged 12 Through 17
streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.
Novavax and partner SK bioscience will provide the first protein-based COVID-19 vaccine approved for use in adolescents aged 12 through 17 years in South Korea GAITHERSBURG, Md., Aug. 12, 2022 /PRNewswire/ Novavax, Inc. (Nasdaq: NVAX), a biotechnology company dedicated to developing and commercializing next-generation vaccines for serious infectious diseases, today announced that partner, SK bioscience, has received a Post Approval Change Application approval from the Korean Ministry of Food and Drug Safety (KMFDS) for Nuvaxovid (NVX-CoV2373) COVID-19 vaccine for active immunization to prevent coronavirus disease 2019 (COVID-19) caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) in adolescents aged 12 through 17. "Today's approval in South Korea is an important step in ensuring broad global access to a protein-based vaccine option," said Stanley C. Erck, President and Chief Executive Officer, Novavax. "We are pleased to collaborate with SK b